CARLSBAD, Calif.–(BUSINESS WIRE)–Nov 26, 2012–GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, will present at the Canaccord Genuity Medical Technology & Diagnostics Forum to be held at the Le Parker Meridien in New York, NY on December 4, 2012.
Hany Massarany, President and Chief Executive Officer, will present at 11:00 a.m. Eastern time (8:00 a.m. Pacific time) with a question and answer session scheduled immediately following the presentation. During the presentation, the company will discuss business and financial developments and trends.
A live webcast and audio archive of the presentation will be available at www.genmarkdx.com. A replay of the webcast will be available on the company’s website for 90 days or can be viewed by visiting Canaccord Genuity.
About GenMark Diagnostics, Inc.
GenMark Diagnostics is a leading provider of automated, multiplex molecular diagnostic testing systems that detect and measure DNA and RNA targets to diagnose disease and optimize patient treatment. Utilizing GenMark’s proprietary eSensor® detection technology, GenMark’s eSensor XT-8™ system is designed to support a broad range of molecular diagnostic tests with a compact, easy-to-use workstation and self-contained, disposable test cartridges. GenMark currently markets four tests that are FDA cleared for IVD use: Cystic Fibrosis Genotyping Test, Respiratory Viral Panel, Thrombophilia Risk Test, and Warfarin Sensitivity Test. A number of other tests, including HCV Genotyping, 2C19 Genotyping, and 3A4/3A5 Genotyping are in development. For more information, visit www.genmarkdx.com.
Safe Harbor Statement This press release includes forward-looking statements regarding events, trends, and business prospects, which may affect our future operating results and financial position. Such statements including, but not limited to, those regarding our growth strategy, are all subject to risks and uncertainties that could cause our actual results and financial position to differ materially from those expressed or implied by such statements. Some of these risks and uncertainties include, but are not limited to, our research and development plans and timelines, including those with respect to our NexGen platform, risks related to our history of operating losses, the need for further financing and our ability to access the necessary additional capital for our business, inherent risk and uncertainty in the protection of our intellectual property rights, and regulatory uncertainties regarding approval or clearance for our products, as well as other risks and uncertainties described under the “Risk Factors” in our public filings with the Securities and Exchange Commission. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.
CONTACT: GenMark Diagnostics, Inc.Hany Massarany President, Chief Executive Officer 760-448-4358
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA NEW YORK
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY GENETICS MEDICAL DEVICES
SOURCE: GenMark Diagnostics, Inc.
Copyright Business Wire 2012
PUB: 11/26/2012 09:00 AM/DISC: 11/26/2012 09:00 AM http://www.businesswire.com/news/home/20121126005107/
